ReviewInternational journal of molecular sciences2025
The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Temporomandibular Disorder-like Pain in Parkinson's Disease Is Associated with Motor Symptom Severity and Disability Levels.Journal of clinical medicine · 2026Article
- Neuroprotective role ofFrontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder due to damage of the nigrostriatal pathway and consequent dopamine (DA) deficiency. The main classic symptoms are those related to motor disturbances, such as postural instability, resting tremor, bradykinesia, and muscle rigidity. Other symptoms, such as non-motor symptoms, do not attract the attention of clinicians and are often overlooked, remaining undiagnosed and untreated, even though they can significantly impair quality of life of PD patients. Dopaminergic therapy is primarily aimed at treating motor symptoms, although it can bring measurable benefits for various non-motor problems. This narrative review analyzes the scientific literature and describes the most recent information on the impact of dopaminergic therapy on non-motor symptoms in PD; both its beneficial and undesirable effects. We discuss evidence that non-motor symptoms such as cardiovascular dysfunction, thermoregulatory issues, dysphagia and drooling, urinary symptoms, pain, neuropsychiatric symptoms, and sleep disorders, including obstructive sleep apnea, can be effectively treated with various dopaminergic strategies, while noting the contraindications and adverse effects of these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.